Navigation Links
Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
Date:2/17/2011

EAST BRUNSWICK, N.J., Feb. 17, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer of Savient will present at the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011, at 4:00 p.m. Eastern Time.  The conference will be held at the New York Hilton in New York, NY.  

A live webcast of the presentation can be accessed through the investor relations section of the Company's website www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
11. Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 ... the addition of the  "Global Hormone Replacement ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,Hormone replacement ... a means of replacing hormones that are ... This type of therapy is usually initiated ...
(Date:8/21/2014)... , Aug. 21, 2014 Mathematic studies at the ... University , and funded by the Jeffrey Epstein VI ... tumors can be visually identified for elimination. These aggressive cells ... study, which shows a topological map of what to look ... cancer research, for while tumor cells can be extracted from ...
(Date:8/21/2014)... Bulgaria (PRWEB) August 21, 2014 ... released today by Ontotext . Now the ... semantic analysis of structured and unstructured data is available ... the cost of enterprise technology. Organizations that do not ... for data management can use S4 since there is ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... Nanotechnology products and processes were unveiled at the ... the fifty-second anniversary celebrations of the Asian Institute ... of Excellence in Nanotechnology (CoEN) at AIT, Prof. ... processes demonstrates potential development of Thailand as a ...
... 2011 "ALBERT EINSTEIN" World Award of Science to Professor ... Professor University of Toronto, Canada. The members ... the winner of the 2011 "ALBERT EINSTEIN" World Award ... of nanochemistry that have helped to define and establish ...
... 2011 ThermoGenesis Corp. (NASDAQ: KOOL ), ... stem cells, announced today it will report financial results for the ... Monday, September 12, 2011. Company,s Conference Call ... call Monday, September 12, 2011 at 2:00 PM Pacific (5:00 PM ...
Cached Biology Technology:AIT unveils portfolio of 16 nanotechnology products 22011 Awards of World Cultural Council 22011 Awards of World Cultural Council 32011 Awards of World Cultural Council 42011 Awards of World Cultural Council 5ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011 2
(Date:8/20/2014)... Knoxville, research finds life can persist in a cold, ... of a team that examined waters and sediments from ... and found the extreme environment supports microbial ecosystems. ... and her colleagues has implications for life in other ... system. The findings are published in the current edition ...
(Date:8/20/2014)... of Tbingen, Arizona State University, the Wellcome Trust Sanger ... (Swiss TPH) isolated Mycobacterium pinnipedii from skeletons ... old. The pathogen is a relative of the TB ... in humans today. These researchers assume that seals carried ... link to sea lions was unexpected" comments Sebastien Gagneux, ...
(Date:8/20/2014)... MA Using population-based screening outcomes of approximately 3 ... including four researchers at the University of Massachusetts Medical ... immunodeficiency (SCID) can be successfully implemented across public health ... published in the Aug. 20 issue of the ... ) showed the rate of SCID in newborns is ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... of California, Berkeley, chemists have found a smoking gun proving ... responsible for a dramatic rise in atmospheric nitrous oxide, which ... Climate scientists have assumed that the cause of the ... the soil to convert nitrogen to nitrous oxide at a ...
... Although nuclear waste has been produced for a long ... highly toxic material, which remains hazardous for up to 130 ... and Legitimacy. Nihilism and Responsibility, Mats Andrn, professor in History ... the nuclear waste issue from a humanistic perspective. The ...
... CLEVELAND In a first-of-its-kind clinical trial, physician-scientists ... Center and Case Western Reserve University School of Medicine ... cancer screening. The five-year study is recruiting patients to ... colonoscopy for detecting large colon polyps. ...
Cached Biology News:Fertilizer use responsible for increase in nitrous oxide in atmosphere 2Fertilizer use responsible for increase in nitrous oxide in atmosphere 3Fertilizer use responsible for increase in nitrous oxide in atmosphere 4Postpone the nuclear waste decision 2New clinical trial explores novel noninvasive colon cancer screening test 2New clinical trial explores novel noninvasive colon cancer screening test 3
... Mouse L1210 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
ID clarifier: Without ethidium bromide...
... Systems provide rapid, precise localization of ... frozen or paraffin-embedded tissue, cytospins and ... facilitate double or triple labeleing experiments, ... with primary antibodies of different animal ...
...
Biology Products: